Core Viewpoint - The stock price of Kangtai Biological fell by 2.17% to 17.56 yuan on August 6, 2025, with a trading volume of 226,069 hands and a transaction amount of 399 million yuan [1] Company Overview - Kangtai Biological specializes in the research, production, and sales of human vaccines, with key products including recombinant hepatitis B vaccine and Haemophilus influenzae type b conjugate vaccine [1] - The company is located in Shenzhen, Guangdong Province, and operates within the biopharmaceutical industry [1] Shareholder Activity - The controlling shareholder's concerted actor, Yuan Liping, reduced her holdings by 11,031,900 shares from July 23 to August 6, 2025, accounting for 0.99% of the total share capital, with an average reduction price of 17.44 yuan per share [1] - After the completion of this reduction plan, Yuan Liping retains 17.07% of the company's shares [1] Financial Performance - In the first quarter of 2025, the company reported operating revenue of 645 million yuan and a net profit attributable to the parent company of 22.43 million yuan [1] Capital Flow - On August 6, 2025, the net outflow of main funds was 79.20 million yuan, with a cumulative net outflow of 120.56 million yuan over the past five days [1]